Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (241-250 of 266) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
Nature Biotechnology|January 15, 2020
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigensGeoffrey M Lynn, Christine Sedlik, Faezzah Baharom, et al.
Pageof 27

Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
Nature Biotechnology|January 15, 2020
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigensGeoffrey M Lynn, Christine Sedlik, Faezzah Baharom, et al.
Pageof 27